2024-05-15T07:08:25-05:00 2023-12-31 BDO USA 200 OTTAWA AVE NW STE 300 GRAND RAPIDS MI 49503 990 2023-01-01 352711268 Intrepid Alliance Inc C/O BROWNE CONSULTING GROUP % BROWNE CONSULTING GROUP INTR 7817572081 ONE BROADWAY Suite 14TH FL CAMBRIDGE MA 01242 JAMES BERGIN TREASURER 7817572081 2024-05-06 true JAMES BERGIN 999009999 true Jacob Cook P01240455 6167747000 2 2023 2023-04-26 12:10:37Z JAMES ANDERSON ONE BROADWAY 14TH FL CAMBRIDGE MA 01242 1500000 false X INTREPIDALLIANCE.ORG X 2021 DE PROMOTE THE COMMON BUSINESS INTEREST OF ITS MEMBERS OF ADVANCING GLOBAL HEALTH SECURITY THROUGH ANTIVIRAL PANDEMIC PREPAREDNESS EFFORTS. 8 8 0 26 0 0 0 0 1499980 1500000 0 0 0 0 1499980 1500000 0 0 0 0 134220 319996 0 0 0 102030 983248 236250 1303244 1263730 196756 1648182 1913894 29052 98008 1619130 1815886 X THE PRIMARY PURPOSE OF THE CORPORATION IS TO PROMOTE THE COMMON BUSINESS INTEREST OF ITS MEMBERS OF ADVANCING GLOBAL HEALTH SECURITY THROUGH PANDEMIC PREPAREDNESS EFFORTS. THE CORPORATION WILL PURSUE THIS PURPOSE BY PROMOTING THE DEVELOPMENT OF NEW TREATMENTS FOR EMERGING VIRAL PANDEMIC PATHOGENS THROUGH COORDINATED EARLY SCIENCE, POLICY AND ADVOCACY, STAKEHOLDER ENGAGEMENT THAT FACILITATES INFORMATION SHARING, AND ADVANCING AND CREATING EFFICIENCIES IN EARLY RESEARCH AND DEVELOPMENT AMONG ITS MEMBERS AND OTHERS IN THE ANTIVIRAL R&D ECOSYSTEM. IN THIS WAY THE CORPORATION AIMS TO SUPPORT THE 100 DAY MISSION, AN INTERNATIONAL EFFORT BY THE INTERNATIONAL PANDEMIC PREPAREDNESS SECRETARIAT(IPPS.ORG) "TO PREPARE AS MUCH AS POSSIBLE SO THAT WITHIN THE FIRST 100 DAYS A PANDEMIC THREAT IS IDENTIFIED AN INITIAL REGIMEN OF THERAPEUTICS" CAN BE MADE AVAILABLE BY RESEARCH ENTERPRISES THAT ARE SAFE, EFFECTIVE AND AFFORDABLE. false false BEYOND COVID-19, GLOBALIZATION, URBAN EXPANSION, AND EXPLOITATION OF NATURAL HABITATS SUGGEST HUMANITY WILL FACE NEW FORMS OF RESPIRATORY AND OTHER PATHOGENS THAT HOLD THE POTENTIAL TO CAUSE PANDEMICS. ORALLY AVAILABLE SMALL-MOLECULE ANTIVIRAL DRUGS FOR RAPID MOBILIZATION AND DISTRIBUTION ARE A CRITICAL TOOL TO PROTECT SOCIETIES FROM ANOTHER VIRAL PANDEMIC. UNLIKE SOME VACCINES AND ANTIBODIES, ANTIVIRAL THERAPIES MIGHT BE LESS PRONE TO THE IMPACT OF VIRUS GENETIC EVOLUTION, MAY BE EFFECTIVE AGAINST A BROAD RANGE OF VIRUSES, AND CAN CHANGE THE COURSE OF DISEASE EVEN AFTER INFECTION. MOST SMALL MOLECULE ANTIVIRALS CAN BE PRODUCED RAPIDLY AND COST-EFFECTIVELY AT A GLOBAL SCALE IN EXISTING FACILITIES, BUT THEY REQUIRE YEARS TO DISCOVER AND DEVELOP, SO IT IS CRITICAL TO PROMOTE AND SUPPORT RESEARCH, ADVOCACY, AND SCIENTIFIC INFORMATION SHARING ACROSS THE ACADEMIC BIOTECH AND PHARMACEUTICAL INDUSTRY. IN ORDER TO CREATE EFFICIENCIES IN THE R&D ECOSYSTEM, THE CORPORATION WILL COLLABORATE WITH PARTNERS IN OTHER SECTORS AND ITS MEMBERS IN EXPLORING REDUNDANCIES AND OPPORTUNITIES TO COLLABORATE FOR THE BENEFIT OF HUMANITY SUCH AS SHARING NEW RESEARCH FINDINGS, CREATING GUIDELINES SUCH AS TARGET PRODUCT PROFILES, BENCHMARKING GLOBAL R&D EFFORTS AGAINST PATHOGENS OF PANDEMIC CONCERN AND CREATING A LISTING OF PROMISING LEAD PRODUCT CANDIDATES BY RESEARCHERS GLOBALLY. WE HOPE TO ACCELERATE THE COLLECTIVE UNDERSTANDING OF VIRAL TARGETS AND INCREASE THE LIKELIHOOD OF THE R&D ECOSYSTEM IN IDENTIFYING PROMISING LEADS. THE CORPORATION INTENDS TO FACILITATE FURTHER SCIENTIFIC INFORMATION SHARING BY DEVELOPING WHITE PAPERS ON RELEVANT TOPICS, PERFORMING A LANDSCAPE AND NEEDS ASSESSMENT ACROSS PUBLIC AND PRIVATE ANTIVIRAL RESEARCH SECTORS, AND PROVIDING KNOWLEDGE-SHARING OPPORTUNITIES THROUGH ORGANIZING MEETINGS AND SEMINARS. THE CORPORATION ALSO ORGANIZED AND PRODUCED A GLOBAL SUMMIT ON ANTIVIRAL PREPAREDNESS FOR 100 STAKEHOLDERS, PUBLISHED AND DISSEMINATED THE ANTIVIRAL SUMMIT PROCEEDINGS AND RECOMMENDATIONS, RESEARCHED, ANALYZED AND AUTHORED THE ANTIVIRAL CLINICAL DEVELOPMENT LANDSCAPE FOR PUBLICATION IN JANUARY 2024 AND DEVELOPED A TARGET COMPOUND PROFILE TO GUIDE ACADEMIC, BIOTECH, PHARMA AND GOVERNMENT DRUG DEVELOPERS IN THEIR R&D FOR ANTIVIRALS. false false false true false false false false false false false false false false false false false false false true false false false false false false false false true false false false false false false false false false false false false false false true 4 0 true 0 false false false false false false false false X 8 8 false false false false true true false true true false false true true true true false false true false false X X BROWNE CONSULTING GROUP 7817572081 ONE BROADWAY 14TH FL CAMBRIDGE MA 01242 X NINA HILL SECRETARIAT 40.0 0.0 X 319996 0 0 JAMES ANDERSON PRESIDENT 1.0 0.0 X X 0 0 0 JAMES BERGIN TREASURER 1.0 0.0 X X 0 0 0 LYDIA OGDEN SECRETARY 1.0 0.0 X X 0 0 0 KENNETH BRADLEY DIRECTOR (AS OF 12/23) 1.0 0.0 X 0 0 0 TOMAS CIHLAR DIRECTOR 1.0 0.0 X 0 0 0 MARGARET CHU-MOYER DIRECTOR 1.0 0.0 X 0 0 0 RUXANDRA DRAGHIA-AKLI DIRECTOR 1.0 0.0 X 0 0 0 MICHELLE PARKS DIRECTOR 1.0 0.0 X 0 0 0 KUMAR SINGH SAIKATENDU DIRECTOR 1.0 0.0 X 0 0 0 SUJATA VAIDYANATHAN DIRECTOR 1.0 0.0 X 0 0 0 JOHN YOUNG DIRECTOR (THRU 12/23) 1.0 0.0 X 0 0 0 319996 0 0 1 false true false HILL SCIENTIFIC AND PUBLIC AFFAIRS 420 EAST 72ND STREET NEW YORK NY 10021 SECRETARIAT 319996 JOHN C POTTAGE JR 107 DEVON ROAD PAOLI PA 19301 R&D CONSULTANT 154750 COVINGTON AND BURLING PO BOX 3225 CAROL STREAM IL 60132 LEGAL 147070 ROPES GRAY 800 BOYLSTON STREET BOSTON MA 02199 LEGAL 114072 4 0 MEMBERSHIP DUES 621500 1500000 1500000 1500000 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1500000 1500000 0 0 0 0 319996 0 0 0 0 0 0 261956 75087 0 0 0 0 0 16104 49802 0 0 4851 0 195919 0 0 0 0 RESEARCH & DEVELOPMENT 377915 OTHER EXPENSES 1614 1303244 1645787 1787403 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2395 126491 0 0 0 0 0 0 0 0 0 0 0 0 1648182 1913894 29052 98008 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 29052 98008 X 0 0 0 0 1619130 1815886 1619130 1815886 1648182 1913894 196756 X false false false false true false Europe (Including Iceland and Greenland) 0 0 Program Services MEMBERSHIP DUES 500000 0 0 0 0 500000 500000 false false false false false false X X X false false false NINA HILL SECRETARIAT 319996 0 0 0 0 0 0 0 0 0 319996 0 0 0 FORM 990, PART VI, SECTION A, LINE 6: THE ORGANIZATION HAS MEMBERS THAT ARE ENGAGED IN THE PRODUCTION AND/OR DEVELOPMENT OF PHARMACEUTICAL PRODUCTS. FORM 990, PART VI, SECTION A, LINE 7A: THE MEMBERS HAVE THE RIGHT TO VOTE ON THE ADMISSION OF NEW MEMBERS, THE APPOINTMENT OR ELECTION OF DIRECTORS, THE REMOVAL OF DIRECTORS AND THE ADOPTION, AMENDMENT, CHANGE OR REPEAL OF THE ORGANIZATION'S ORGANIZING DOCUMENTS. FORM 990, PART VI, SECTION B, LINE 11B: THE ORGANIZATION'S FORM 990 IS PROVIDED TO THE BOARD FOR REVIEW PRIOR TO FILING. FORM 990, PART VI, SECTION B, LINE 12C: The Corporation's Board has adopted a conflict of interest policy that requires officers and directors of the Corporation to, on an annual basis, sign a statement affirming that they have received a copy of the policy, have read and understand the policy, and have agreed to comply with the policy. FORM 990, PART VI, SECTION B, LINE 15A: 990's were reviewed for comparable fees for consultants who serve as CEO, Executive Director or Secretariat; Consultant hourly rates were also compared to hourly rates of comparable consultants in life sciences. The Chair and Treasurer reviewed and approved the hourly rate and based upon the number of hours spent working in 2022 and based upon the strategic work plan for 2023 a target range of hours was arrived at. The rate was approved by the Finance Committee and by the board. A written contract was executed in 2022. FORM 990, PART VI, SECTION B, LINE 19: The Corporation makes these documents available upon written request to the Secretary.